FDA Approves Galliprant, a New Animal Drug for Osteoarthritis in Dogs

The U.S. Food and Drug Administration today announced the approval of Galliprant
(grapiprant tablets), a new animal drug intended to control pain and inflammation associated with osteoarthritis in dogs.

A new treatment option for dogs with OA, Galliprant is a prostaglandin E2 (PGE2) EP4 receptor antagonist; a non-cyclooxygenase inhibiting, non steroidal anti-inflammatory drug (NSAID). All NSAIDs carry certain risks, including vomiting, diarrhea, not eating/eating less, and lethargy. These drugs must be prescribed by a licensed veterinarian, because professional expertise is needed to diagnose and provide guidance in the control of OA pain

Mode d'action du Grapiprant sur la sensibilisation périphérique

Mode d'action du Grapiprant sur la sensibilisation périphérique

How to Score the Canine BPI: Pain Interference

The Canine BPI measures how much pain interferes with six daily activities, including general activity, enjoyment of life, rising to standing, walking, running, and climbing. The Canine BPI pain interference score is the mean of the six interference items. This mean can be used if more than two-thirds, or four of six, of the total items have been completed on a given administration.

How to Score the Canine BPI: Pain Severity

The Canine BPI assesses pain at its “worst,” “least,” “average,” and “now” (current pain). In clinical trials, these items have each been used singly to represent pain severity; however model validation for the Canine BPI included all four items. The responses to these items are averaged to deliver a pain severity score.